Pneumology - Original Articles Open access

Chronic obstructive pulmonary disease and heart failure in real life: the tip of the iceberg in the sea of comorbidities. A prospective observational study

Authors

Published
4 February 2025
Section
Pneumology - Original Articles

Abstract

Chronic obstructive pulmonary disease (COPD) and heart failure (HF) are two of the most common conditions treated in internal medicine. Although it is known that these diseases often coexist, the specific characteristics of the affected patients and the prognostic implications are not yet well understood. Managing patients with both COPD and HF requires an integrated treatment approach. The aim of the study was to examine the association between COPD and HF. We conducted a prospective observational cohort study. All consenting patients admitted to the Internal Medicine Department from the Emergency Department with known or strongly suspected COPD were enrolled. A total of 144 patients were included, with 47.2% of them also having HF, distributed among the various HF subcategories as follows: 10.4% with HF with reduced ejection fraction (HFrEF), 3.5% with HF with mild-reduced ejection fraction, and 33.3% with HF with preserved ejection fraction (HFpEF). This result is consistent with the literature, which suggests a higher prevalence of COPD in patients with HFpEF compared to HFrEF. A Doppler echocardiography was performed during hospitalization. Some variables showed a statistically significant difference when comparing patients with COPD and HF to those with COPD without HF. Interestingly, the follow-up at 3 and 6 months post-discharge revealed higher mortality in patients with HF, with an odds ratio (95% confidence interval) of 10.0 (1.2-82.2). This study could contribute to a better understanding of the prognostic implications arising from the coexistence of COPD and HF, emphasizing the importance of a patient-centered approach in managing multiple comorbidities.

Ethics Approval

The study was performed in accordance with the Declaration of Helsinki and local regulations. The study was approved by local ethical committee (n. 24860_oss).

References

  1. Adeloye D, Chua S, Lee C, et al. Global and regional estimates of COPD prevalence: Systematic review and meta–analysis. J Glob Health 2015;5:020415. DOI: https://doi.org/10.7189/jogh.05.020415
  2. Ntritsos G, Franek J, Belbasis L, et al. Gender-specific estimates of COPD prevalence: a systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis 2018;13:1507-14. DOI: https://doi.org/10.2147/COPD.S146390
  3. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015;385:117-71. DOI: https://doi.org/10.1016/S0140-6736(14)61682-2
  4. Shahim B, Kapelios CJ, Savarese G, Lund LH. Global public health burden of heart failure: an updated review. Card Fail Rev 2023;9:e11. DOI: https://doi.org/10.15420/cfr.2023.05
  5. Naeije R. Pulmonary hypertension and right heart failure in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005;2:20-2. DOI: https://doi.org/10.1513/pats.200407-037MS
  6. McCullough PA, Hollander JE, Nowak RM, et al. Uncovering heart failure in patients with a history of pulmonary disease: rationale for the early use of B-type natriuretic peptide in the emergency department. Acad Emerg Med 2003;10:198-204. DOI: https://doi.org/10.1111/j.1553-2712.2003.tb01990.x
  7. Rutten FH, Cramer M-JM, Grobbee DE, et al. Unrecognized heart failure in elderly patients with stable chronic obstructive pulmonary disease. Eur Heart J 2005;26:1887-94. DOI: https://doi.org/10.1093/eurheartj/ehi291
  8. Bernabeu-Wittel M, Para O, Voicehovska J, et al. Competences of internal medicine specialists for the management of patients with multimorbidity. EFIM multimorbidity working group position paper. Eur J Intern Med 2023;109:97-106. DOI: https://doi.org/10.1016/j.ejim.2023.01.011
  9. Kotlyarov S. Analysis of the comorbid course of chronic obstructive pulmonary disease. J Pers Med 2023;13:1179. DOI: https://doi.org/10.3390/jpm13071179
  10. Fabbri LM, Celli BR, Agustí A, et al. COPD and multimorbidity: recognising and addressing a syndemic occurrence. Lancet Respir Med 2023;11:1020-34. DOI: https://doi.org/10.1016/S2213-2600(23)00261-8
  11. Sin DD. Chronic obstructive pulmonary disease as a risk factor for cardiovascular morbidity and mortality. Proc Am Thorac Soc 2005;2:8-11. DOI: https://doi.org/10.1513/pats.200404-032MS
  12. Güder G, Störk S. COPD and heart failure: differential diagnosis and comorbidity. Herz 2019;44:502-8. DOI: https://doi.org/10.1007/s00059-019-4814-7
  13. De Miguel-Díez J, Chancafe Morgan J, Jimenez-Garcia R. The association between COPD and heart failure risk: a review. Int Chron Obstruct Pulmon Dis 2013;305-12. DOI: https://doi.org/10.2147/COPD.S31236
  14. Shah S, Vanclay F, Cooper B. Improving the sensitivity of the Barthel Index for stroke rehabilitation. J Clin Epidemiol 1989;42:703-9. DOI: https://doi.org/10.1016/0895-4356(89)90065-6
  15. McDonagh TA, Metra M, Adamo M, et al. 2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. G Ital Cardiol 2024;25:202-13. [Article in Italian]. DOI: https://doi.org/10.15829/1560-4071-2023-5168
  16. National Cancer Institute. Definition of pack year. 2011. Available from: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/pack-year.
  17. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83. DOI: https://doi.org/10.1016/0021-9681(87)90171-8
  18. GOLD. 2023 GOLD report. Global Initiative for Chronic Obstructive Lung Disease - GOLD. Available from: https://goldcopd.org/2023-gold-report-2/.
  19. Chiumeo F, Folloni S. Chronic obstructive pulmonary disease and heart failure: research and clinical practice in primary care. Ital J Med 2015;9:346-8. DOI: https://doi.org/10.4081/itjm.2015.560
  20. Nozzoli C, Anastasio L, Fabbri LM, et al. Complexity of patients with chronic obstructive pulmonary disease hospitalized in internal medicine: a survey by FADOI. Ital J Med 2015;9:120-4. DOI: https://doi.org/10.4081/itjm.2015.516
  21. Hawkins NM, Petrie MC, Jhund PS, et al. Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. Eur J Heart Fail 2009;11:130-9. DOI: https://doi.org/10.1093/eurjhf/hfn013
  22. Mentz RJ, Kelly JP, Von Lueder TG, et al. Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction. J Am Coll Cardiol 2014;64:2281-93. DOI: https://doi.org/10.1016/j.jacc.2014.08.036
  23. Ather S, Chan W, Bozkurt B, et al. Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. J Am Coll Cardiol 2012;59:998-1005. DOI: https://doi.org/10.1016/j.jacc.2011.11.040
  24. Beghé B, Verduri A, Roca M, Fabbri LM. Exacerbation of respiratory symptoms in COPD patients may not be exacerbations of COPD. Eur Respir J 2013;41:993-5. DOI: https://doi.org/10.1183/09031936.00180812
  25. Aisanov Z, Khaltaev N. Management of cardiovascular comorbidities in chronic obstructive pulmonary disease patients. J Thorac Dis 2020;12:2791-802. DOI: https://doi.org/10.21037/jtd.2020.03.60
  26. Redfield MM, Borlaug BA. Heart failure with preserved ejection fraction: a review. JAMA 2023;329:827-38. DOI: https://doi.org/10.1001/jama.2023.2020
  27. Chirinos JA. Exercise training in heart failure with preserved ejection fraction: is the peripheral vasculature involved? JACC Heart Fail 2023;11:465-8. DOI: https://doi.org/10.1016/j.jchf.2023.01.022
  28. Rucker D, Joseph J. Defining the phenotypes for heart failure with preserved ejection fraction. Curr Heart Fail Rep 2022;19:445-57. DOI: https://doi.org/10.1007/s11897-022-00582-x
  29. Vaduganathan M, Docherty KF, Claggett BL, et al. SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomized controlled trials. Lancet 2022;400:757-67. DOI: https://doi.org/10.1016/S0140-6736(22)01429-5
  30. Labaki WW, Xia M, Murray S, et al. NT-proBNP in stable COPD and future exacerbation risk: Analysis of the SPIROMICS cohort. Respir Med 2018;140:87-93. DOI: https://doi.org/10.1016/j.rmed.2018.06.005
  31. Ozaki AF, Ko DT, Chong A, et al. Prescribing patterns and factors associated with sodium-glucose cotransporter-2 inhibitor prescribing in patients with diabetes mellitus and atherosclerotic cardiovascular disease. CMAJ Open 2023;11:E494-503. DOI: https://doi.org/10.9778/cmajo.20220039
  32. Andrijevic I, Milutinov S, Lozanov Crvenkovic Z, et al. N-terminal prohormone of brain natriuretic peptide (NT-proBNP) as a diagnostic biomarker of left ventricular systolic dysfunction in patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Lung 2018;196:583-90. DOI: https://doi.org/10.1007/s00408-018-0137-3
  33. Schneider A, Gantner L, Maag I, et al. Are ICD-10 codes appropriate for performance assessment in asthma and COPD in general practice? Results of a cross sectional observational study. BMC Health Serv Res 2005;5:11. DOI: https://doi.org/10.1186/1472-6963-5-11
  34. d’Avila Melo SM, de Oliveira LA, Wanderley JLF, Rocha RDA. Evaluating the extremely elderly at a pulmonary function clinic for the diagnosis of respiratory disease: frequency and technical quality of spirometry. J Bras Pneumol 2019;45:e20180232. DOI: https://doi.org/10.1590/1806-3713/e20180232
  35. Chukowry PS, Spittle DA, Turner AM. Small airways disease, biomarkers and COPD: where are we? Int J Chron Obstruct Pulmon Dis 2021;16:351-65. DOI: https://doi.org/10.2147/COPD.S280157
  36. Rahman HH, Rashid MH, Miah NA, et al. Correlation study between COPD and heart failure in elderly patient. Mymensingh Med J 2022;31:498-505.
  37. Hannink JD, van Helvoort HA, Dekhuijzen PN, Heijdra YF. Heart failure and COPD: partners in crime? Respirology 2010;15:895-901. DOI: https://doi.org/10.1111/j.1440-1843.2010.01776.x
  38. Ventrella F, Mastroianni F, Errico M. Chronic obstructive pulmonary disease pathways as a tool to improve appropriateness in internal medicine departments. Ital J Med 2015;9:96-108. DOI: https://doi.org/10.4081/itjm.2014.448
  39. López-Pardo ME, Candal-Pedreira C, Valdés-Cuadrado L, et al. Factors related with hospital attendance and mortality in patients with COPD: a case-control study in a real-life setting. Int J Chron Obstruct Pulmon Dis 2022;17:809-19. DOI: https://doi.org/10.2147/COPD.S355236
  40. Pezzuto A, Ricci A, D'Ascanio M, et al. Short-term benefits of smoking cessation improve respiratory function and metabolism in smokers. Int J Chron Obstruct Pulmon Dis 2023;18:2861-5. DOI: https://doi.org/10.2147/COPD.S423148

Metrics

Citations and online attention from Dimensions, Altmetric and PlumX.